The Sudan virus, a close relative of Ebola, has a fatality rate of 50% but remains poorly understood in terms of how it infects cells. Currently, no approved treatments exist. To address this critical gap in pandemic preparedness, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center investigated how this deadly virus attaches to human cells.

Like Ebola, the Sudan virus enters cells by binding to NPC1, a protein responsible for cholesterol transport. Using cryo-electron microscopy, the researchers mapped how the Sudan virus interacts with the human NPC1 receptor. Their findings revealed that four key amino acid differences in the receptor-binding proteins of Sudan and Ebola viruses enable the Sudan virus to bind to human NPC1 with nine times greater affinity than Ebola, which may contribute to its high fatality rate.

Building on this discovery, the team predicted the receptor-binding affinities of three other filoviruses closely related to Sudan and Ebola. They also examined how the Sudan virus binds to NPC1 receptors in bats, which are believed to be natural hosts of filoviruses. These findings provide crucial insights into the infection mechanisms and evolutionary origins of Sudan virus and related filoviruses, paving the way for potential treatments.

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, affecting millions of people worldwide. Due to the complexity and variability of the disease, there are major challenges in the treatment of HCC in its intermediate and advanced stages; despite advances in various treatment modalities, there are still gaps in our understanding of effective therapeutic strategies. Key findings from several studies have shown that the combination of immunotherapy and targeted therapy has a synergistic anti-tumor effect, which can significantly enhance efficacy with a favorable safety profile. In addition, other studies have identified potential biomarkers of therapeutic response, such as tumor protein 53 (TP53) and CTNNB1 (encoding β-conjugated proteins), thus providing personalized treatment options for patients with intermediate and advanced hepatocellular carcinoma. The aim of this article is to review the recent advances in the treatment of intermediate and advanced HCC, especially targeted immune-combination therapy, chimeric antigen receptor T cell therapy (CAR-T cell therapy), and gene therapy for these therapeutic options that fill in the gaps in our knowledge of effective treatment strategies, providing important insights for further research and clinical practice.

Hepatocellular carcinoma is a common malignant tumor, ranking sixth and fifth in incidence globally and in China, respectively. It ranks among the top three in mortality and has long been recognized as a global challenge. HCC is the most common type of liver cancer, accounting for 75% to 80% of cases. Its incidence and mortality vary significantly across regions, which is closely related to risk factors such as viral hepatitis (e.g., hepatitis B and C), alcoholic and non-alcoholic cirrhosis, and fatty liver. Treatment options for HCC include surgical resection, percutaneous anhydrous ethanol injection, Transcatheter arterial embolization (TACE), ablative therapy, chemotherapy and liver transplantation. Early stage HCC can be completely cured by surgery, but about 70% of patients have progressed to an intermediate and advanced stage at the time of diagnosis and are unable to undergo surgery.